Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

18.46 +0.27 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
3 Stocks That Could Soar in a Santa Claus Rally
These stocks are primed for a holiday surge. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
3 Top Stocks to Buy Hand Over Fist Before the End of 2022
You probably shouldn't wait for long to buy these stocks. 
Via The Motley Fool
5 Top Stocks for December
From game-changing products to indisputable growth catalysts, this list of top stocks has something for all. 
Via The Motley Fool
12 Top Stocks to Buy in December
Add this dandy dozen to your stocking this month. 
Via The Motley Fool
Where NovoCure Stands With Analysts
Via Benzinga
Why Novocure Stock Is Jumping Today
Novocure's innovative cancer therapy picked up a big win in Canada. 
Via The Motley Fool
5 Analysts Have This to Say About NovoCure
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
Via Benzinga
FedEx To Rally Over 25%? Here Are 10 Other Price Target Changes For Tuesday
Keybanc lowered Salesforce, Inc. (NYSE: CRM) price target from $210 to $200. . Keybanc analyst Michael Turits maintained an Overweight rating on the stock. Salesforce shares gained 0.5% to $154.45 in... 
Via Benzinga
3 Growth Stocks to Buy That Could Skyrocket
The future looks promising for all three of these stocks. 
Via The Motley Fool
Novocure Stock: Bull vs. Bear
The company's technology has a lot of potential. But does its stock? 
Via The Motley Fool
What 4 Analyst Ratings Have To Say About NovoCure
Analysts have provided the following ratings for NovoCure (NASDAQ:NVCR) within the last quarter: 
Via Benzinga
Where NovoCure Stands With Analysts
NovoCure (NASDAQ:NVCR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Novocure (NVCR) Q3 2022 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2022. 
Via The Motley Fool
2 Potentially Explosive Stocks to Buy in November
Both Novocure and MercadoLibre could have good news on the way. 
Via The Motley Fool
NovoCure's Return On Capital Employed Insights
NovoCure (NASDAQ:NVCR) brought in sales totaling $131.00 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 10.7%, resulting in a loss of $26.58 million. 
Via Benzinga
3 Unstoppable Stocks That Could Double in 5 Years
The opportunities for these innovators are tremendous. 
Via The Motley Fool
NovoCure: Q3 Earnings Insights
NovoCure (NASDAQ:NVCR) reported its Q3 earnings results on Thursday, October 27, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings NovoCure beat estimated earnings... 
Via Benzinga
Why Novocure Stock Is Sinking Today
An analyst's downgrade is weighing on the biotech company. 
Via The Motley Fool
CSX To Rally 20%? Here Are 5 Other Price Target Changes For Monday
Raymond James raised CSX Corporation (NASDAQ: CSX) price target from $31 to $33. Raymond James analyst Patrick Tyler Brown maintained the stock with an Outperform rating. CSX shares rose 1.7% to close... 
Via Benzinga
The Clock Is Ticking to Buy This Game-Changing Stock at a Discount
This stock could soon skyrocket. 
Via The Motley Fool
Recap: NovoCure Q2 Earnings
  NovoCure (NASDAQ:NVCR) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022
Upgrades 
Via Benzinga
3 Unstoppable Stocks You Can Buy Now for Less Than $100
They might not be available so cheaply for too much longer. 
Via The Motley Fool
NovoCure Earnings Perspective: Return On Capital Employed
NovoCure (NASDAQ:NVCR) brought in sales totaling $140.87 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 416.63%, resulting in a loss of $24.01 million. 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2022
Upgrades 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.